Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Rhus verniciflua Stokes (RVS) and butein induce apoptosis of paclitaxel-resistant SKOV-3/PAX ovarian cancer cells through inhibition of AKT phosphorylation

BMC Complementary and Alternative Medicine volume 16, Article number: 122 (2016) Cite this article

Abstract

Background

Rhus verniciflua Stokes (RVS) belongs to the Anacardiaceae family and traditionally used for cancer treatment. RVS and butein, a major compound of RVS, were known to induce apoptosis via AKT inhibition in cancer cells. Thus, in this study, we investigated the effect of RVS and its derivative compounds (fisetin, quercetin, butein) on cell death in SKOV-3/PAX cells.

Methods

The 80 % ethanol extract of RVS and its derivative compounds (fisetin, quercetin, butein) were prepared. The cytotoxicity was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. Apoptotic cells were detected by staining with propidium iodide (PI) and Annexin V-fluorescein isothiocyanate/7-aminoactinomycin D (Annexin V-FITC/7-AAD). The expression level of intracellular signaling related-proteins in apoptosis and growth were measured by western blot assay.

Results

We found that RVS and butein suppressed the growth of SKOV-3/PAX cells in a dose-dependent manner. We also found that RVS and butein produced the cleavage of caspase-9, -8, -3, and PARP. Similarly, sub-G1 phase and Annexin V-FITC positive cells were increased by RVS and butein. Moreover, RVS and butein significantly reduced AKT phosphorylation in SKOV-3/PAX cells. PI3K inhibitor LY294002 caused PARP cleavage supporting our finding.

Conclusion

Our data clearly indicate that RVS and butein induce apoptosis of SKOV-3/PAX cells through inhibition of AKT activation. RVS and butein could be useful compounds for the treatment for paclitaxel resistant-ovarian cancer.

Peer Review reports

Background

Cancer is one of disease and is the second leading cause of death all over the world [1, 2]. Although the incidence of ovarian cancer is the eighth in developed and developing countries in women. However, the mortality rate for ovarian cancer is the fifth and higher in more developed countries than less developed countries. Further reductions in cancer death rates can be improved by applying various therapies including surgery, radiation chemotherapy, hormonal therapy, and chemotherapy [3].

One of the most common chemotherapy agent used for the treatment of ovarian cancer patients are taxanes, such as paclitaxel [4, 5]. Despite many studies on therapy for decades, there are still considerable problems to be solved such as multi-drug resistant (MDR) [6, 7]. MDR plays a key role in chemotherapy because of existing anti-cancer drugs effectiveness wearing of as tumor build tolerance to them. Although ovarian cancer is sensitive to paclitaxel in early days, tumors ultimately are not in patients because of MDR [8, 9]. One of the acquisition mechanisms to paclitaxel is known as activation of the AKT [10, 11]. Phosphorylated AKT (p-AKT) is lead to an increase in cell growth but it inhibits cell death [12, 13]. Accordingly, the combination of AKT inhibitors with chemotherapy agent has been shown to sensitize ovarian cancer patients [14, 15].

Rhus verniciflua Stokes (RVS) has many useful effects such as it loosen the extravasated blood in the liver, control inflammation, and help the digestive organs in Donguibogam or a botanical list. Moreover, RVS is documented to be used for treating various diseases such as obesity, allergic inflammatory, allergic contact dermatitis, swelling, angiogenesis, Parkinson’s disease, Huntington’s disease, and cancer [16–18]. RVS is composed of diverse compounds such as butein, fisetin and quercetin [19].

Previous studies have demonstrated that RVS and butein induce cell death via AKT pathway in cancer cells [20, 21]. However, it is not reported that RVS or butein is lead to cell death through blocking AKT activation in paclitaxel-resistant ovarian cancer cells. In this study, we wanted to know that whether RVS of ethanol extracted can be induced apoptosis in paclitaxel resistant ovarian cancer. We have shown that RVS was inhibited AKT-mediated proliferation via inducing apoptosis. Moreover, butein, a compound of RVS, showed the same results as the RVS. Therefore, our results indicate that RVS and butein may be potential anticancer drug for paclitaxel resistant ovarian cancer.

Methods

Plant materials

Toxicodendron vernicifluum Stokes, formerly known as Rhus verniciflua Stokes (RVS) and the common name is Chinese lacquer tree. RVS belongs to the Anacardiaceae family and deciduous tree species [19, 22]. It is about 10 ~ 20 meter in height and divided into yellow endothelial and gray outer. The purpose of its cultivation is mainly used to paint with lacquer collected the sap or get wax from the fruit. Before you use it for food or medicine, it should be removed completely toxic due to the poisonous of RVS [23].

Preparation of RVS extracts and chemical compounds

80 % ethanol extract of RVS used in this research was provided from Hanpoong pharm (Jeonju, Republic of Korea). The powder form of RVS was dissolved in 30 % ethanol to make a stock solution and stored at -80 °C until ready for use. Fisetin (PubChem CID: 5281614) and quercetin (PubChem CID: 5280343) were purchased from Sigma (St. Louis, MO). Butein (PubChem CID: 5281222) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Cell lines and cell culture

The paclitaxel resistant ovarian cancer cells, SKOV-3/PAX cells were provided by Prof. Cho. These cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % heat-inactivated fetal bovine serum (FBS), 1 % antibiotic-antimycotic solution, and 5nM of paclitaxel in a humidified atmosphere of 5 % CO2 at 37 °C.

Cell proliferation assay

For cell proliferation assay, SKOV-3 or SKOV-3/PAX were seeded at 5x103 cells in 96 well plates and then treated with paclitaxel (0, 1,10, 100 and 1000nM), RVS (0, 50, 100, 200 and 500 μg/mL), or butein (0, 2.5, 5 and 10 μg/mL) for 72 hours. Thereafter, cell viability was performed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay with an absorbance at 570 nm.

FACS analysis

Dead cells were measured by propidium iodide (PI) staining because PI is bound to DNA and can be used to detect abnormal cell populations. SKOV-3/PAX cells were treated with RVS and butein for 24 hours, and then fixed 70 % ethanol in ice-cold PBS at -20 °C. Next day, the fixed cells were resuspended in PBS containing 50 μg/mL of PI and 50 μg/mL of RNAse A, and incubated in the dark for 15 minutes at room temperature. The DNA contents of samples were analyzed by FACSCalibur flow cytometer (Becton-Dickinson, San Jose, CA). Apoptotic dead cells were detected by Annexin V-fluorescein isothiocyanate (FITC) and 7-aminoactinomycin D (7-AAD) staining. Annexin V-FITC, staining for phosphatidylserine (PS) in cell membrane, is detected in early apoptosis. 7-AAD is a membrane impermeability dye that is generally stained apoptotic cells and excluded viable cells. SKOV-3/PAX cells were treated with RVS and butein, and then harvested in Annexin V binding buffer. The samples were stained with Annexin V-FITC in the dark for 15 minutes at room temperature and gave more staining with 7-AAD in the same way. 2-dimensional staining to measure apoptosis and necrosis was subjected to FACSCalibur.

Western blot

Whole lysates, proteins extracted from SKOV-3/PAX were separated by 10-15 % SDS-PAGE according to their molecular weights. Each protein was transferred to nitrocellulose blotting membrane and blotted by appropriate antibodies for following molecules at 4 °C; Anti-cleaved caspase-9 (sc22182), -p-p38 (sc7973), -p-JNK (sc6254), -ERK (sc1647), and -p-ERK (sc7383) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-cleaved caspase-8 (#9496), -cleaved caspase-3 (#9661), -PARP (#9542), -p-Raf-1 (#9421), -AKT (#9272), -p-AKT (S473) (#9271), -JNK (#3708), and -p38 (#9212) antibodies were obtained from Cell Signaling Technology (Danver, MA, USA). Anti-α-tubulin (T5168) antibody was purchased from Sigma (St. Louis, MO). Next day, the membranes were washed three times in phosphate buffered saline with 0.01 % tween-20 (PBST) and incubated at room temperature for 1 hour with secondary antibodies. The membranes were then washed with PBST three times and visualized the protein bands using an enhanced chemiluminescence detection system (DoGen-Bio, Seoul, Korea) and exposed to X-ray film (Agfa-Gevaert N.V., Mortsel, Belgium).

Statistical analysis

All experimental data were shown as mean ± SD and analyzed by Student t-test using Microsoft excel software. P value less than 0.05 was considered statistically significant.

Results

RVS inhibits cell proliferation in chemoresistant SKOV-3 cells

We first examined that whether SKOV-3/PAX cells were acquired resistant to paclitaxel from parental cells. As shown in Fig. 1a, paclitaxel inhibited growth of SKOV-3 cells, but not in SKOV-3/PAX cells. Next, we treated with RVS to identify the anti-proliferation effects in paclitaxel-resistant cells. As shown in Fig. 1b, RVS suppressed in a-dose dependently cell growth in SKOV-3/PAX cells. Therefore, our results indicate that RVS effectively inhibits the proliferation of paclitaxel-resistant ovarian cancer cells.

Fig. 1
figure 1

Proliferation of parental and paclitaxel resistant ovarian cancer cells by paclitaxel or RVS treatment for 72 hours. a The effect of paclitaxel on the viability in SKOV-3 or SKOV-3/PAX cells was determined by MTT assay. b The effect of RVS on the viability in SKOV-3/PAX cells was determined by MTT assay (mean ± SD; n = 6). *, p < 0.05 versus control in parental. **, p < 0.05 versus control in resistant

Full size image

RVS induces apoptosis in paclitaxel-resistant ovarian cancer cells

To determine whether RVS could induce the cell death in SKOV-3/PAX cells, we were treated at various concentrations of RVS. First, we were stained DNA by PI and detected dead cells. The sub-G1 phases, dead cells, were increased by RVS in a dose-dependently manner. Especially, dead cell population showed that 500 μg/ml of RVS induced the sub-G1 phase to 20.4 % compared with control (Fig. 2a). Next, in order to whether RVS induces cell death inducing apoptosis or necrosis, we performed Annexin V-FITC and 7-AAD staining. SKOV-3/PAX cells were stained with Annexin V-FITC and 7-AAD, and then measured the proportion of apoptosis and necrosis-related cell death (Fig. 2b). As a result, it was increased the cell death due to apoptosis more than necrosis. Lastly, we were observed the change of apoptosis-related proteins. Cleaved form of PARP, caspase-9, -8, and -3 were increased by RVS treatment in SKOV-3/PAX cells (Fig. 2c). Therefore, our data show that RVS induces apoptosis through the caspase-dependent pathway.

Fig. 2
figure 2

RVS induces apoptotic-cell death in paclitaxel resistant ovarian cancer cells for 24 hours. a Left panel, the cytotoxic effect of RVS in SKOV-3/PAX cells was determined by PI staining assay. Right panel, data represent quantitative results for left panel (mean ± SD; n = 3). *, p < 0.05. b The dead cells were differentiated between apoptosis and necrosis by Annexin V-FITC and 7-AAD dual staining. c The expression of procaspase-9, cleaved caspase-9, cleaved caspase-8, procaspase-3, caspase-3, and PARP in cell lysates from SKOV-3/PAX cells treated with RVS was determined by Western blot assay

Full size image

Butein suppresses cell proliferation and enhances apoptosis in paclitaxel-resistant ovarian cancer cells

We also wanted to know that whether which compounds of RVS was induced cell death in paclitaxel resistant ovarian cancer cells. As shown in Fig. 3a, butein significantly reduced cell growth than other compounds of RVS, such as fisetin or quercetin. It is reported that fisetin induces apoptosis in human non-small cell lung cancer via inhibiting MAPK signaling pathway and quercetin increases the apoptosis rate of ovarian cancer cells [24, 25]. To confirm whether butein caused apoptotic cell death, we treated with butein on SKOV-3/PAX cells. Like RVS, butein dose-dependently increased sub-G1 phase (Fig. 3b) and induced the apoptotic-cell death (Fig. 3c). Moreover, butein increased levels of activated caspase-9, -8, -3, and cleaved PARP in SKOV-3/PAX cells (Fig. 3d). Therefore, our data demonstrate that butein is the active compound of RVS and contributes to paclitaxel-resistant ovarian cancer cell apoptosis via caspase-dependent signaling.

Fig. 3
figure 3

The effect of apoptosis in butein-treated SKOV-3/PAX cells. (a) The effect of butein, fisetin, and quercetin on the viability in SKOV-3/PAX cells for 72 hours was determined by MTT assay. (b) The cytotoxic effect of butein in SKOV-3/PAX cells for 24 hours was determined by PI staining assay. Bottom panel, data represent quantitative results for top panel (mean ± SD; n = 3). *, p < 0.05 versus control. (c) The dead cells were differentiated between apoptosis and necrosis by Annexin V- FITC and 7-AAD dual staining. (d) The expression of procaspase-9, cleaved caspased-9, cleaved caspase-8, procaspase-3, caspase-3, and PARP in cell lysates from SKOV-3/PAX cells treated with butein were determined by Western blot assay

Full size image

RVS and butein disrupt cell growth via AKT pathway in paclitaxel-resistant ovarian cancer cells

Further our understanding of the molecular effect of RVS or butein in growth control, we performed cells were treated with RVS or butein for 24 hours. When SKOV-3/PAX cells were treated with RVS, phosphorylation of AKT were reduced in a time-dependently manner (Fig. 4a). But phosphorylation of ERK was induces by RVS. In the case of butein, phosphorylation of ERK and p38 were decreased as well as AKT activity (Fig. 4b). Our data showed that inhibition of AKT activity was decreased by both RVS and butein, also the AKT signaling pathway is well known as a key role in cancer cell growth. Therefore, we showed that inhibition of AKT phosphorylation using by AKT inhibitor, LY294002, the PARP cleaved was increased by as much as RVS and butein (Fig. 4c). These results demonstrated that RVS and butein are inducing apoptosis through AKT signaling pathway (Fig. 4d).

Fig. 4
figure 4

RVS and butein inhibit AKT signaling in SKOV-3/PAX cells for 2 hours. (a and b) The expression of AKT, Raf-1, ERK, p38, and JNK in cell lysates from SKOV-3/PAX cells treated with RVS or butein were determined by Western blot assay. (c) SKOV-3/PAX cells were pretreated with AKT inhibitor, LY294002 (50 μM) for 1 hour and then added with RVS or butein for another 24 hours. The expression levels of AKT phosphorylation and PARP cleavage were determined by Western blot assay. (d) A schematic model for the apoptosis via inhibition of AKT activity by RVS or butein

Full size image

Discussion

Numerous reports are shown that AKT phosphorylation is induced in ovarian cancer patients and paclitaxel-treated in ovarian carcinoma cells. Induction of AKT activation causes tumorigenesis and becomes a problem for treating cancer [26, 27]. It must be treated together inhibiting of AKT activity as well as increasing apoptosis [28, 29]. Recent studies showed that RVS reduces AKT phosphorylation in gastric cancer cell lines [30] and that n-butanol extract form RVS decreases LPS-induced AKT activation in macrophage RAW 264.7 cells [31]. Therefore, we evaluated the effects of RVS in paclitaxel-resistant ovarian cancer cell lines.

The results indicate that RVS was lead to apoptosis via both accumulation of cleaved PARP form and suppression of AKT activation in a dose-dependent manner. Furthermore, we conducted experiments to know what compounds of RVS have these capabilities. Among the three compounds, butein effected best, reducing the proliferation of SKOV-3/PAX cells. Butein, a bioactive flavonoid [32, 33], was effective for cancer treatment through apoptosis pathway such as caspases and PARP. Also, Butein affected the cell proliferation via repressing AKT phosphorylation in cervical cancer cells and AKT-dependent phosphorylation of hTERT in leukemia cells [32, 34]. It is reported that other compounds, fisetin and quercetin, induce apoptosis in cancer cells, but slightly inhibited proliferation in SKOV-3/PAX cells [24, 25]. Lastly, after treatment of SKOV-3/PAX cells with PI3K inhibitor LY294002, the function of AKT was repressed. The result is RVS and butein can induce SKOV-3/PAX cell apoptosis by reducing AKT pathway activation. Accordingly, the present study suggested that the inhibiting AKT phosphorylation is a key role for the apoptosis of paclitaxel-resistant ovarian cancer cells.

Conclusion

We show that RVS and its active compound, butein, may enhance apoptosis and reduce proliferation through the inhibition of AKT activation in paclitaxel resistant-ovarian cancer. Therefore, our results suggested that RVS could be useful for the chemotherapy of drug-resistant cancer and more researches are needed to further a detailed mechanism.

Ethics

This study used cell lines commercially available, thereby not requiring the ethics.

Availability of data and materials

Data are all contained within the paper.

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  2. Torre L, Siegel RL, Jemal A. Global Cancer Facts & Figures. 3rd ed. Atlanta: American Cancer Society; 2015.

    Google Scholar 

  3. Li Y, Jiang Y, Wan Y, Zhang L, Tang W, Ma J, Wu S, Cheng W. Medroxyprogestogen enhances apoptosis of SKOV-3 cells via inhibition of the PI3K/Akt signaling pathway. J Biomed Res. 2013;27(1):43–50.

    Article  CAS  PubMed  Google Scholar 

  4. DiSaia PJ, Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol. 2003;90(2 Pt 2):S24–32.

    Article  CAS  PubMed  Google Scholar 

  5. Lin YH, Chen BY, Lai WT, Wu SF, Guh JH, Cheng AL, Hsu LC. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(1):19–31.

    Article  CAS  PubMed  Google Scholar 

  6. Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. J Clin Invest. 2013;123(10):4131–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sui H, Fan ZZ, Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 2012;40(2):426–35.

    Article  CAS  PubMed  Google Scholar 

  8. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;15:55–61.

    Google Scholar 

  9. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 1997;48:353–74.

    Article  CAS  PubMed  Google Scholar 

  10. Ling X, Bernacki RJ, Brattain MG, Li F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem. 2004;279(15):15196–203.

    Article  CAS  PubMed  Google Scholar 

  11. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002;5(6):234–48.

    Article  CAS  PubMed  Google Scholar 

  12. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem. 2002;277(36):33490–500.

    Article  CAS  PubMed  Google Scholar 

  13. Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C, Dorigo O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken). 2010;67(8):535–44.

    CAS  Google Scholar 

  14. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23(34):5853–7.

    Article  CAS  PubMed  Google Scholar 

  15. Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, et al. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. Mol Cancer Res. 2015;13(4):795–806.

    Article  CAS  PubMed  Google Scholar 

  16. Choi W, Jung H, Kim K, Lee S, Yoon S, Park J, Kim S, Cheon S, Eo W, Lee S. Rhus verniciflua stokes against advanced cancer: a perspective from the Korean Integrative Cancer Center. J Biomed Biotechnol. 2012;2012:874276.

    Article  PubMed  Google Scholar 

  17. Hong MH, Kim JH, Lee SY, Go HY, Kim JH, Shin YC, Kim SH, Ko SG. Early antiallergic inflammatory effects of Rhus verniciflua Stokes on human mast cells. Phytother Res. 2010;24(2):288–94.

    PubMed  Google Scholar 

  18. Park DK, Lee YG, Park HJ. Extract of Rhus verniciflua Bark Suppresses 2,4-Dinitrofluorobenzene-Induced Allergic Contact Dermatitis. Evid Based Complement Alternat Med. 2013;2013:879696.

    PubMed  PubMed Central  Google Scholar 

  19. Kim JH, Shin YC, Ko SG. Integrating traditional medicine into modern inflammatory diseases care: multitargeting by Rhus verniciflua Stokes. Mediators Inflamm. 2014;2014:154561.

    PubMed  PubMed Central  Google Scholar 

  20. Khan N, Adhami VM, Afaq F, Mukhtar H. Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo. Antioxid Redox Signal. 2012;16(11):1195–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Na CH: Molecular mechanism by which Rhus Verniciflua Stokes induces apoptosis in SK-OV-3/PAC, chemoresistance ovarian cells. 2015:1-29. http://www.dcollection.net/handler/khu/000000164759

  22. Shin SH, Koo KH, Bae JS, Cha SB, Kang IS, Kang MS, Kim HS, Heo HS, Park MS, Gil GH, et al. Single and 90-day repeated oral dose toxicity studies of fermented Rhus verniciflua stem bark extract in Sprague-Dawley rats. Food Chem Toxicol. 2013;55:617–26.

    Article  CAS  PubMed  Google Scholar 

  23. Byun JS, Han YH, Hong SJ, Hwang SM, Kwon YS, Lee HJ, Kim SS, Kim MJ, Chun W. Bark Constituents from Mushroom-detoxified Rhus verniciflua Suppress Kainic Acid-induced Neuronal Cell Death in Mouse Hippocampus. Korean J Physiol Pharmacol. 2010;14(5):279–83.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Kang KA, Piao MJ, Madduma Hewage SR, Ryu YS, Oh MC, Kwon TK, Chae S, Hyun JW. Fisetin induces apoptosis and endoplasmic reticulum stress in human non-small cell lung cancer through inhibition of the MAPK signaling pathway. Tumour Biol 2016; pp 1-10. DOI 10.1007/s13277-016-4864-x

  25. Ren MX, Deng XH, Ai F, Yuan GY, Song HY. Effect of quercetin on the proliferation of the human ovarian cancer cell line SKOV-3. Exp Ther Med. 2015;10(2):579–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13(22):2905–27.

    Article  CAS  PubMed  Google Scholar 

  27. Urban BC, Collard TJ, Eagle CJ, Southern SL, Greenhough A, Hamdollah-Zadeh M, Ghosh A, Poulsom R. BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling. 2015. DOI 10.1136/gutjnl-2014-308270

  28. Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des. 2010;16(12):1410–6.

    Article  CAS  PubMed  Google Scholar 

  29. Zhang W, Cai J, Chen S, Zheng X, Hu S, Dong W, Lu J, Xing J, Dong Y. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway. Mol Med Rep. 2015;12(1):1506–14.

    CAS  PubMed  Google Scholar 

  30. Kim JH, Go HY, Jin DH, Kim HP, Hong MH, Chung WY, Park JH, Jang JB, Jung H, Shin YC, et al. Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines. Cancer Lett. 2008;265(2):197–205.

    Article  CAS  PubMed  Google Scholar 

  31. Jung CH, Kim JH, Kim JH, Chung JH, Choi HS, Seo JB, Shin YC, Kim SH, Ko SG. Anti-inflammatory effect of Rhus verniviflua Stokes by suppression of iNOS-mediated Akt and ERK pathways: in-vitro and in-vivo studies. J Pharm Pharmacol. 2011;63(5):679–87.

    Article  CAS  PubMed  Google Scholar 

  32. Bai X, Ma Y, Zhang G. Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway. Oncol Rep. 2015;33(6):3085–92.

    CAS  PubMed  Google Scholar 

  33. Song NJ, Yoon HJ, Kim KH, Jung SR, Jang WS, Seo CR, Lee YM, Kweon DH, Hong JW, Lee JS, et al. Butein is a novel anti-adipogenic compound. J Lipid Res. 2013;54(5):1385–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Moon DO, Kim MO, Lee JD, Choi YH, Kim GY. Butein suppresses c-Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett. 2009;286(2):172–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from Korean Medicine R&D project of the Ministry Of Health and Welfare (B120014).

Author information

Authors and Affiliations

  1. Department of Science in Korean Medicine, Graduate School, Kyung Hee University, 1 Hoegi, Seoul, 130-701, Korea

    Hyeong Sim Choi & Min Kyoung Kim

  2. Jeju International Marine Science Center for Research and Education, Korea Institute of Ocean Science & Technology (KIOST), Jeju, 695-975, Korea

    Youn Kyung Choi

  3. Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, 1 Hoegi, Seoul, 130-701, Korea

    Youn Kyung Choi, Yong Cheol Shin & Seong-Gyu Ko

  4. Department of Biotechnology, Korea National University of Transportation, 61 Daehakro, Jeungpyeong-gun, Chungbuk, 368-701, Korea

    Sung-Gook Cho

Authors
  1. Hyeong Sim Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Kyoung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Youn Kyung Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Cheol Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sung-Gook Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seong-Gyu Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Sung-Gook Cho or Seong-Gyu Ko.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

HSC designed the research, performed all laboratory experiments, analyzed data, and drafted the manuscript. SGC conceived the experiments, analyzed data, and revised the manuscript. MKK assisted all laboratory experiments. YKC helped to modify the manuscript. YCS carried out the literature search and SGK supervised the research. All authors have read and approved the final manuscript.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Choi, H.S., Kim, M.K., Choi, Y.K. et al. Rhus verniciflua Stokes (RVS) and butein induce apoptosis of paclitaxel-resistant SKOV-3/PAX ovarian cancer cells through inhibition of AKT phosphorylation. BMC Complement Altern Med 16, 122 (2016). https://doi.org/10.1186/s12906-016-1103-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-016-1103-3

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us